8-K: Semler Scientific Settles DOJ Claims, Faces Revenue Drop

Semler Scientific agrees to a $29.75 million settlement with the DOJ over False Claims Act allegations and anticipates a significant revenue decline due to customer reductions and delayed FDA clearance.

Summary

• Settled alleged civil violations of the False Claims Act with the U.S. Department of Justice and HHS for $29.75 million, plus 4.25% interest from April 28, 2025.
• Agreed to pay $390,000 for relators' attorneys' fees and costs within seven business days.
• Entered into a five-year Corporate Integrity Agreement with the Office of Inspector General (OIG) of HHS, requiring compliance measures and reporting.
• Anticipates third-quarter 2025 revenues between $6.9 million and $7.5 million.
• Expects fourth-quarter 2025 revenues to be at least 50% lower than Q3 2025 expected revenue, primarily due to a significant customer reducing QuantaFlo device usage effective October 1, 2025.
• New 510(k) clearance from the FDA for expanded QuantaFlo labeling, intended as an aid in the diagnosis of other cardiovascular diseases, is not expected until midto late 2026 at the earliest.
• A class-action lawsuit was filed on August 29, 2025, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 related to the timing and extent of disclosure of the DOJ claim.

Sentiment

Score: 2

Explanation: The filing contains multiple significant negative events: a large financial settlement, a substantial and immediate revenue decline forecast, a delayed key product approval, and a new class-action lawsuit. While the settlement resolves a past issue, the forward-looking financial and operational challenges are severe.

Positives

• Resolution of the False Claims Act allegations through a settlement agreement, avoiding protracted litigation.
• No admission of wrongdoing in connection with the allegations.
• Release from civil or administrative monetary claims for the covered conduct, subject to certain exceptions.

Negatives

• Payment of a $29.75 million settlement amount, plus 4.25% interest from April 28, 2025, within 14 business days.
• Payment of $390,000 for relators' attorneys' fees and costs within seven business days.
• Anticipated significant reduction in fourth-quarter 2025 revenues (at least 50% lower than Q3 2025) due to a major customer's reduced usage of QuantaFlo.
• Third-quarter 2025 revenues are expected to be lower, in the range of $6.9 million to $7.5 million, reflecting a gradual decrease.
• Delay in new FDA 510(k) clearance for expanded QuantaFlo labeling, not expected until midto late 2026 at the earliest.
• A class-action lawsuit has been filed against the company and officers, alleging securities law violations related to disclosure timing.
• Costs associated with the settlement, investigation, defense, and Corporate Integrity Agreement are deemed unallowable for government contracting and federal healthcare programs.

Risks

• Risks inherent with obtaining a new 510(k) clearance from FDA for expanded indications.
• Challenges in financing the settlement agreement payments through borrowings under the Coinbase facility and ATM offering program.
• Ongoing class action litigation and its potential financial and reputational impact.
• Risks associated with investing in Bitcoin, including Bitcoin's volatility, if the company implements a Bitcoin treasury strategy.
• Risk that insurance plans and additional customers will not continue to license its cardiovascular testing products or license new FDA-cleared products and services.
• Risk of further changes in the reimbursement landscape for its products.
• Risks related to its indebtedness, including potential borrowing under the Master Loan Agreement with Coinbase Credit Inc.

Future Outlook

The company anticipates a significant decline in fourth-quarter 2025 revenues, projected to be at least 50% lower than Q3 2025, primarily due to a major customer's reduced usage of its QuantaFlo device. New FDA 510(k) clearance for expanded QuantaFlo labeling is not expected until midto late 2026 at the earliest. The company intends to use cash from operations, proceeds from its ATM equity offering, and potentially borrow from Coinbase Credit Inc. to fund the settlement payment.

Management Comments

• Semler Sci denies any liability or misconduct and intends to vigorously defend the litigation.

Industry Context

The medical device industry, particularly in diagnostics, is heavily influenced by regulatory changes and reimbursement policies. The decreased usage of QuantaFlo devices by Semler Scientific is directly attributed to the 2024 Medicare Advantage and Part D Final Rate Announcement by CMS, highlighting the significant impact of government healthcare policy on company revenues. The pursuit of new FDA 510(k) clearance for expanded labeling is a common strategy for medical device companies to broaden market access and mitigate risks from specific reimbursement changes, though the delayed timeline presents a challenge. The False Claims Act settlement underscores the stringent compliance requirements for companies interacting with federal healthcare programs, a common risk across the industry.

Corporate Governance

Legal Proceedings

• Settlement of alleged civil violations of the False Claims Act with the U.S. Department of Justice and HHS for $29.75 million, plus interest and attorneys' fees.
• A class-action lawsuit, Ravi Krishnamoorthy v. Semler Scientific, Inc., et al., was filed on August 29, 2025, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, challenging the timing and extent of disclosure regarding the DOJ claim. Semler Sci denies liability and intends to vigorously defend.

Stakeholder Impact

• Shareholders: Significant negative impact due to the large settlement payment, substantial revenue decline, delayed product approval, and new class-action lawsuit, likely leading to share price volatility and potential dilution from ATM offering.
• Customers: A significant customer is reducing usage of QuantaFlo, indicating potential dissatisfaction or impact from CMS reimbursement changes. Other customers may also be affected by changes in the reimbursement landscape.
• Employees: Potential for operational restructuring or cost-cutting measures due to revenue decline. Increased compliance burden from the Corporate Integrity Agreement.
• Regulatory Authorities (DOJ, HHS, OIG, FDA): Successful settlement of False Claims Act allegations, but ongoing monitoring through the Corporate Integrity Agreement. FDA clearance process continues for QuantaFlo.
• Relators: Will receive a share of the settlement proceeds ($5.2 million plus interest) and attorneys' fees ($390,000).

Next Steps

• Pay the $29.75 million settlement amount plus interest within 14 business days.
• Pay $390,000 for relators' attorneys' fees within seven business days.
• Institute certain compliance and other measures and provide reporting to OIG for a five-year period under the Corporate Integrity Agreement.
• Continue seeking new 510(k) clearance from the FDA for expanded labeling of QuantaFlo.
• Vigorously defend against the class-action lawsuit.
• File a Joint Stipulation of Dismissal of the Civil Action as to Semler upon receipt of the settlement payment.
• Identify and adjust previously submitted cost reports for unallowable costs within 90 days of the effective date of the settlement agreement.

Key Dates

Recommendation

The filing reveals a confluence of highly negative events that severely impact Semler Scientific's financial health and operational outlook. The $29.75 million False Claims Act settlement, coupled with a projected revenue decline of at least 50% in Q4 2025 due to a major customer's withdrawal, indicates a significant deterioration of the core business. The delay in FDA clearance for an expanded QuantaFlo indication until mid-to-late 2026 removes a near-term growth catalyst. Furthermore, the new class-action lawsuit adds legal uncertainty and potential further financial liabilities. The need to potentially raise capital through an ATM offering or borrowing from Coinbase suggests liquidity pressure. These factors collectively point to substantial downside risk and a highly unfavorable investment outlook.

Keywords

Semler Scientific, SMLR, SEC Filing, 8-K, False Claims Act, DOJ Settlement, Medicare Part B, QuantaFlo, FloChec, Revenue Guidance, FDA Clearance, 510(k), Class Action Lawsuit, Corporate Integrity Agreement, Healthcare Devices, Cardiovascular Disease, Medical Device, Reimbursement, Litigation, Financial Outlook